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Abstract The pathogenesis of evolution from episodic
migraine (EM) to chronic migraine (CM) has not yet been
clearly determined. Some studies revealed that dysfunction
of the brainstem may play a role. We aimed to determine
the brainstem 1H-MR spectroscopic (MRS) findings in
episodic and chronic migraine. We recruited patients with
EM, CM and controls. Patients with CM were divided into
subgroups with and without medication overuse (MO). The
1H-MRS metabolite ratios at the periaqueductal gray
(PAG) and bilateral dorsal pons were measured and com-
pared with those in controls. A total of 19 patients with
EM, 53 patients with CM (with MO n = 30, without MO
n = 23) and 16 control subjects completed the study.
Patients with EM had the highest N-acetylaspartate (NAA)/
creatine (Cr) ratio at the dorsal pons (right, P = 0.014; left,
P = 0.034) in comparison with those of CM and controls.
The latter two groups did not differ. Among migraine
patients, NAA/Cr ratios at dorsal pons were inversely
correlated with headache frequency (right, r = -0.350,
P = 0.004; left, r = -0.284, P = 0.019) and inten-
sity (right, r = -0.286, P = 0.019; left, r = -0.244,
P = 0.045), but not disease duration. In contrast, the
metabolite ratios did not differ at the PAG among the study
groups. Of note, MO was not associated with brainstem
MRS ratios in patients with CM. The increased NAA/Cr
levels may suggest neuronal hypertrophy at the dorsal pons
in EM. A progressive dysfunction of this region may occur
from EM to CM since the levels declined with increasing
headache frequency and intensity.
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Introduction
Migraine is traditionally recognized as a purely episodic
disorder that patients are left without sequela [1]. A lon-
gitudinal population-based study has shown that about
2.5 % of patients with episodic migraine (EM) progress to
chronic migraine (CM) annually [2], defined as headache
attacks C15 days/month with C8 days of migraine attacks,
for more than 3 months [3]. CM is associated with more
severe disability, higher medical costs, lower quality of
life, higher percentages of psychiatric comorbidities, and
possibly a higher risk of brain damage [4–7]. Though many
risk factors such as obesity and medication overuse (MO)
have been identified, the mechanism of disease evolution is
still unknown [8].
Brainstem has been suggested as ‘‘the generator’’ of
migraine attacks [9–14]. Functional neuroimaging studies
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have shown the activation of the brainstem during migraine
attacks, either spontaneous or triggered [9–12]. Struc-
tural changes at the periaqueductal gray (PAG) and dorsal
pons have also been reported in patients with migraine
[13, 14]. In contrast, the involvement of brainstem may not
be specific for migraine, since activation and struc-
tural changes are also identified in other pain disorders
[15, 16].
We conducted a study of proton MR spectroscopy
(1H-MRS) over the PAG and dorsal pontine regions in
patients with EM or CM (with or without MO). 1H-MRS
can provide regional metabolite levels including N-acet-
ylaspartate (NAA), choline containing phospholipids
(Cho), creatine and phosphocreatine (Cr), etc. that can be
used to investigate the pathophysiology of neurological
disorders [17, 18]. NAA/Cr is generally considered to be a
marker of neurons, being reduced in conditions where there
is neuronal loss or dysfunction [19, 20]. Serum NAA level
has been reported lower in patients with migraine, com-
pared with that in patients with tension-type headache and
healthy controls [21]. Cho/Cr can be viewed as an indirect
marker of myelination and cell membrane metabolism
[19, 20]. By recruiting both patients with EM and CM, we
aimed to investigate the metabolite changes in the brain-
stem, which might shed light on the mechanism of
migraine evolution. In addition, we also tested if there was
any relationship between brainstem and MO, a known risk
factor of migraine evolution.
Methods
Subjects
We recruited patients from the Headache Clinic at Taipei
Veterans General Hospital (VGH). The diagnoses of EM
and CM (with or without MO) were made according to the
International Classification of Headache Disorders, 2nd
edition (code 1.1 and A1.5.1) (ICHD-2) [3, 22]. MO was
defined as C10 or 15 days of using abortive agents per
month for more than 3 months [22]. Demographics,
headache characteristics, body mass index (BMI), Beck
Depression Inventory (BDI) and Migraine Disability
Assessment Scale (MIDAS) were recorded in a structured
questionnaire before the MRS study. The monthly head-
ache frequency and pain intensity (0–10 numerical rating
scale) were recorded. Age and sex-similar healthy subjects
were recruited from the colleagues of Taipei-VGH as
controls, who had no headache or had infrequent tension-
type headache, i.e. \1 day per month [22]. The study
protocol was approved by the Institutional Review Board
of Taipei-VGH. Each subject provided written informed
consent before entering the study.
Multi-voxel 1H-MRS of PAG and bilateral dorsal pons
All intracranial two-dimensional multi-voxel MRS studies
using point-resolved spectroscopy (PRESS) localization
(TR 1,000 ms, TE 144 ms, FOV 24 cm, 18 9 18 phase
encoding matrices, 1.0 cm section thickness) with auto-
mated shim and water suppression (PROBE-P, Version 8.3,
GE Medical Systems, Milwaukee, WI, USA) were acquired
on a 1.5 T GE Signa Excite scanner. The localized voxels of
interest (VOIs) were placed over the PAG and bilateral
dorsal aspects of the rostral pons (Fig. 1) by the same
neuroradiologist (Lirng JF). The MRS scan was initiated if
the line width reported by the prescan process was less than
6 Hz. Each study lasted up to 7 min including the prescan
process. Off-line spectral post-processing was carried out
using semi-automated software (Probe 2000, Functool,
Version 2.33, GE Medical Systems, Milwaukee, WI, USA).
Spectra were displayed as grids of nominal voxel size
7.5 mm 9 7.5 mm 9 10 mm and overlaid on the conven-
tional MR image used to plan the study. Spectral peaks of
the main metabolites–Cho at 3.2 ppm, Cr at 3.0 ppm and
NAA at 2.0 ppm were analyzed and the ratios between the
metabolites (Cho/Cr and NAA/Cr) were calculated by
Functool automatically.
Statistical analysis
All the statistics were done with the software of SPSS for
Windows version 18.0 (SPSS Inc., Chicago). For continu-
ous data comparison among three groups (control, EM and
CM), one-way analysis of variance (ANOVA) followed by
post hoc analysis with least significant difference (LSD)
method was used. For continuous data comparison between
two groups, independent sample t test was used. For cat-
egorical data, Chi-square test or Fisher’s exact test was
used. Pearson correlation was performed to identify pos-
sible associations between continuous variables. General
linear model (GLM) was used to control confounding




A total of 72 patients with migraine [EM = 19, CM = 53
(with MO = 30, without MO = 23)] and 16 healthy con-
trols were recruited for the study. All patients and controls
were right handed. The demographics and headache pro-
files are listed in Table 1. These three groups were rather
compatible except that patients with CM, compared to
patients with EM, had longer disease duration, more days
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of headache and usage of analgesics per month, and a
higher disability as assessed by MIDAS. Patients with CM
had a nonsignificantly higher BDI score than those with
EM (P = 0.075).
1H-MRS differences among different groups
The results of MRS in the PAG and bilateral dorsal pons
are shown in Table 2. The difference was not significant
for PAG among the three study groups. Regarding dorsal
pons, one outliner data of right dorsal pons was found in
the EM group (NAA/Cr = 4.73, mean/standard deviation
(SD) = 2.02/0.74, z = 3.67; Cho/Cr = 4.75, mean/SD =
1.61/0.82, z = 3.83). The results in Table 2 and the fol-
lowing calculations were done after removal of this outlier
data. NAA/Cr ratio was higher in patients with EM at the
dorsal pons (right side, P = 0.014; left side, P = 0.034) in
comparison with the other two groups. Post hoc analysis
revealed significantly higher ratios in EM patients as
compared with CM patients (right side, P = 0.004; left
Fig. 1 The voxels of interest of
MR spectroscopic study were
located at the periaqueductal
gray matter (a) in midbrain and
bilateral rostral dorsal pons (b)
Table 1 Comparisons of demographics and headache profiles between episodic and chronic migraine patients and normal controls
C, n = 16 EM, n = 19 CM, n = 53 P
Age, years 39.6 ± 8.3 35.2 ± 10.5 40.6 ± 10.5 0.133
Female, n (%) 10 (62.5) 12 (63.2) 44 (83.0) 0.102
Age at onset, years NA 19.4 ± 8.1 21.4 ± 8.4 0.425
Disease duration, years NA 14.3 ± 7.6 19.7 ± 10.1 0.049*
Headache intensitya NA 6.7 ± 2.0 7.1 ± 2.3 0.566
Headache frequency, days/month NA 7.5 ± 3.5 24.7 ± 5.8 \0.001*
Analgesics use, days/month NA 4.1 ± 4.5 16.3 ± 11.7 \0.001*
MIDAS (0–270) NA 19.6 ± 19.5 62.8 ± 56.1 0.005*
BDI score (0–63) NA 9.9 ± 7.5 14.6 ± 9.2 0.075
BMI (kg/m2) NA 22.4 ± 3.4 22.5 ± 5.3 0.930
Unilateral, n (%) NA 12 (66.7) 27 (51.9) 0.278
Throbbing headache, n (%) NA 12 (66.7) 38 (73.1) 0.604
Physical activity aggravation, n (%) NA 15 (83.3) 40 (76.9) 0.568
Associated symptoms
Nausea, n (%) NA 12 (66.7) 37 (71.2) 0.720
Vomiting, n (%) NA 7 (38.9) 26 (50.0) 0.416
Photophobia, n (%) NA 10 (58.8) 35 (67.3) 0.566
Phonophobia, n (%) NA 13 (72.2) 39 (75.0) 1.0
C control, EM episodic migraine, CM chronic migraine, NA not applicable, MIDAS migraine disability assessment scale, BDI Beck depression
inventory, BMI body mass index
* P \ 0.05
a Headache intensity in a 0–10 numerical rating scale
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side, P = 0.017) and controls (right side, P = 0.033; left
side, P = 0.025); whereas, no difference was found
between patients with CM and controls (right side, P =
0.829; left side, P = 0.655). Among all migraine patients
(EM ? CM), significant inverse correlations were found
between dorsal pons NAA/Cr ratios and headache fre-
quency (right side, r = -0.350, P = 0.004; left side,
r = -0.284, P = 0.019) and headache intensity (right
side, r = -0.286, P = 0.019; left side, r = -0.244, P =
0.045). No correlations were noted between NAA/Cr ratios
in dorsal pons and the other variables such as age, gender,
disease duration, onset age, BMI, BDI score, MIDAS score
or other headache profiles. Migraine diagnostic group (EM
vs. CM) was associated with NAA/Cr ratios after control-
ling for age and sex by the GLM analysis. The estimated
differences between EM and CM were 0.203 and 0.151,
adjusted R2 were 0.143 and 0.098 with P values of 0.009
and 0.013 at right and left dorsal pons, respectively. Of
note, the results of these calculations were similar with
even smaller P values after adding back the outlier data of
NAA/Cr in the right dorsal pons.
Medications overuse (MO)
Patients with CM were further divided into those with
(n = 30) and without MO (n = 23). The demographic data
and headache characteristics were compatible between the
two subgroups except for earlier age of onset, longer
duration of illness and more analgesic usage in the MO
subgroup (Table 3). No significant differences in MRS
metabolite ratios at the PAG and dorsal pons were noted
between these two CM subgroups (Table 4).
Discussion
Our study showed higher NAA/Cr ratios at bilateral rostral
dorsal pons in patients with EM than those in patients with
CM and normal controls while the ratios were similar
between the latter two groups. Among all migraine patients,
the NAA/Cr ratios decreased as the headache frequency or
intensity increased, i.e., evolution from EM to CM.
Dorsal pons is the anatomical sites of locus coeruleus
and dorsal raphe, the main nuclei of noradrenergic and
serotonergic systems. Along with the PAG and other
structures, they constitute the descending antinociceptive
network which modulates ascending pain signals to the
brain [23]. Activation of dorsal pons during migraine
attacks has been demonstrated in several studies on patients
with EM [9–12]. One MRI study adopting a higher field
strength (3 Tesla) showed an increase of gray matter vol-
ume at the PAG and dorsal pons in migraine patients with
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with a lower field strength (1.5 Tesla) showed only cortical
but not brainstem gray matter decrease [24]. It is debatable
that in morphometric MRI studies, the changes of the gray
matter could be attributed to the changes of the cell size
(neurons or glia), spine density of neurons or even blood
flow or interstitial fluid [24]. In contrast, our MRS study
results indicate an involvement of the neurons because of
the increment of NAA/Cr levels. It is possible that neurons
at the dorsal pons become hypertrophic after repetitive
activation in patients with EM.
The exact reason why only EM but not CM patients had
higher NAA/Cr levels in the dorsal pons is not clear. If the
above theory is correct, the finding suggests that the neu-
ronal hypertrophy might wane during migraine evolution.
Therefore, CM might result from decompensation after
over-activation of this region, which leads to loss of the
hypertrophic response. It is suggested that the brainstem
dysfunction may alter cortical and subcortical excitability,
which then contributes to migraine evolution [25–28].
Another possibility is that frequent headache attacks might
have a disadvantageous effect on neurons at the dorsal
pons, leading to neuronal dysfunction or atrophy in patients
with CM. In line with the morphometric studies in different
pain disorders, chronic pain is related with a decrease of
cortical gray matter [15, 24]. Among all migraine patients,
our study showed inverse correlations between NAA/Cr
ratios and headache frequency or intensity. This may partly
explain why we did not demonstrate the difference between
normal controls and CM patients. Since this study is of a
cross-sectional design, further longitudinal studies are in
need to validate this finding. Of note, our study did not find
any correlation between NAA/Cr ratio and disease dura-
tion, which suggests that EM even for a long duration does
not jeopardize such function.
The study results failed to demonstrate the difference of
MRS metabolite ratios at the PAG between the two
migraine groups and controls. Previous studies have sug-
gested the PAG as an important player in migraine path-
ogenesis [13, 26]. However, a recent review challenged the
role of the PAG in migraine and argued that there is
‘‘minimally if any’’ activation of the PAG in previous
neuroimaging studies [16]. We could not completely
exclude the possibility of false negativity due to type II
error because patients with EM had nonsignificantly higher
Table 3 Comparisons of
demographics and headache
profiles between chronic




assessment scale, BDI Beck
depression inventory, BMI body
mass index
* P \ 0.05
a Headache intensity in a 0–10
numerical rating scale
Without MO, n = 23 With MO, n = 30 P value
Age, years 37.8 ± 10.9 42.8 ± 9.7 0.086
Female patients, n (%) 18 (78.3) 26 (86.7) 0.419
Age at onset, years 24.4 ± 8.7 19.1 ± 7.5 0.022*
Disease duration, years 14.3 ± 6.2 23.7 ± 10.6 \0.001*
Headache intensitya 6.6 ± 2.6 7.4 ± 2.1 0.265
Headache frequency, days/month 24.1 ± 6.4 25.0 ± 5.4 0.586
Analgesics use, days/month 4.4 ± 4.8 25.0 ± 6.3 \0.001*
MIDAS (0–270) 66.9 ± 61.1 59.5 ± 52.7 0.668
BDI score (0–63) 14.8 ± 11.1 14.4 ± 7.8 0.882
BMI (kg/m2) 22.3 ± 3.7 22.6 ± 6.4 0.836
Unilateral, n (%) 11 (50.0) 16 (53.3) 0.812
Throbbing headache, n (%) 14 (63.6) 24 (80.0) 0.189
Physical activity aggravation, n (%) 19 (86.4) 21 (70.0) 0.166
Associated symptoms
Nausea, n (%) 13 (59.1) 24 (80.0) 0.100
Vomiting, n (%) 10 (45.4) 16 (53.3) 0.575
Photophobia, n (%) 17 (77.3) 18 (60.0) 0.240
Phonophobia, n (%) 18 (81.8) 21 (70.0) 0.518
Table 4 Comparisons of the metabolite ratios of 1H-MR spectroscopy between chronic migraine patients with and without medication overuse
Periaqueductal gray Dorsal pons, right Dorsal pons, left
MO- MO? P MO- MO? P MO- MO? P
NAA/Cr ratio mean (SD) 1.48 (0.15) 1.47 (0.27) 0.903 1.63 (0.20) 1.64 (0.30) 0.842 1.59 (0.18) 1.64 (0.29) 0.458
Cho/Cr ratio mean (SD) 1.24 (0.18) 1.23 (0.21) 0.820 1.36 (0.17) 1.38 (0.48) 0.668 1.32 (0.17) 1.38 (0.27) 0.291
MO medication overuse, NAA N-acetylaspartate, Cr creatine, Cho choline, SD standard deviation
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NAA/Cr level in the PAG compared with the other two
groups (Table 2). We also could not exclude the possible
confounding effect of the inclusion of the aqueduct (and
cerebrospinal fluid) in the VOI of the PAG.
Medication overuse has been recognized as a possible
predictor of migraine transformation, but the mechanism
has not been determined [2, 29]. Among others, dysfunc-
tion of descending antinociceptive network at brainstem
and disturbance of serotonin system has been proposed
[30]. However, our study failed to show any relationship
between MO and brainstem MRS metabolite ratios in
patients with CM.
Our study had limitations that are worth noting. First,
although we focused on locus coeruleus and dorsal raphe,
we could not be certain about the exact relevant substrate
within the placed VOIs because the involvement of sur-
rounding structures could not be avoided. Second, patients
with EM were younger than the other two groups, though
not statistically significant. However, we did not find any
correlations between age and NAA/Cr ratios in our par-
ticipants. Furthermore, the GLM results showed that, after
controlling for the age effect, the migraine diagnostic
groups (EM vs. CM) remained a significant predictor of
NAA/Cr ratios in the dorsal pons. Third, no patients with
migraine with aura were included in the EM group;
therefore, our study results cannot be generalizable to this
patient group. The reason that we recruited only migraine
without aura is for comparison’s sake because migraine
without aura but not migraine with aura is much more
likely to transform to CM according to the ICHD-2 [14].
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